Trial Profile

A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response While Receiving Telaprevir, Peginterferon Alfa2a (Pegasys) and Ribavirin (Copegus).

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary) ; Telaprevir (Primary)
Indications Hepatitis C
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms ILLUMINATE

15 Sep 2011 Results reported in a Vertex Pharmaceuticals media release and published in the New England Journal of Medicine.
20 Jul 2011 Actual initiation date is Oct 2008 added as reported by ClinicalTrials.gov.
25 May 2011 Work productivity results presented at the 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com